{"id":8476,"date":"2020-07-24T10:07:00","date_gmt":"2020-07-24T17:07:00","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=8476"},"modified":"2021-04-05T10:07:54","modified_gmt":"2021-04-05T17:07:54","slug":"safety-and-immunogenicity-of-the-chadox1-ncov-19-vaccine-against-sars-cov-2-a-preliminary-report-of-a-phase-1-2-single-blind-randomised-controlled-trial","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/07\/24\/safety-and-immunogenicity-of-the-chadox1-ncov-19-vaccine-against-sars-cov-2-a-preliminary-report-of-a-phase-1-2-single-blind-randomised-controlled-trial\/","title":{"rendered":"Safety and Immunogenicity of the ChAdOx1 NCoV-19 Vaccine against SARS-CoV-2: A Preliminary Report of a Phase 1\/2, Single-Blind,\u00a0Randomised\u00a0Controlled Trial"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"43\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Folegatti\u00a0present preliminary results of a phase\u00a0<\/span><span data-contrast=\"auto\">1\/2\u00a0<\/span><span data-contrast=\"auto\">single-blind, randomized multi-center (5 UK sites) trial of\u00a0<\/span><span data-contrast=\"auto\">a\u00a0<\/span><span data-contrast=\"auto\">chimpanzee adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein<\/span><span data-contrast=\"auto\">\u00a0(n=543 treatment and n=534)<\/span><span data-contrast=\"auto\">. Controls received a meningococcal conjugate vaccine. Adverse effects\u00a0<\/span><span data-contrast=\"auto\">were more common in the treatment arm and included\u00a0<\/span><span data-contrast=\"auto\">included\u00a0pain, fever, chills, muscle ache, and malaise. No serious adverse events were reported. Cell-mediated immunity peaked on day 14, and humoral (antibody) response rose by day 28 and was boosted by following a second dose\u00a0in\u00a010 participants assigned (non-randomly) to an unblinded boost group. Neutralizing antibody response was detected\u00a0in\u00a0all participants and was strongly associated with antibody levels.\u00a0<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Folegatti\u00a0et al. (July 2020). Safety and Immunogenicity of the ChAdOx1 NCoV-19 Vaccine against SARS-CoV-2: A Preliminary Report of a Phase 1\/2, Single-Blind,\u00a0Randomised\u00a0Controlled Trial.\u00a0<\/span><\/i><i><span data-contrast=\"none\">The\u00a0<\/span><\/i><i><span data-contrast=\"none\">Lancet.\u00a0<\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(20)31604-4\"><span data-contrast=\"none\">https:\/\/doi.org\/10.1016\/S0140-6736(20)31604-4<\/span><\/a><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559685&quot;:720,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Folegatti\u00a0present preliminary results of a phase\u00a01\/2\u00a0single-blind, randomized multi-center (5 UK sites) trial of\u00a0a\u00a0chimpanzee adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein\u00a0(n=543 treatment and n=534). Controls received a meningococcal conjugate vaccine. Adverse effects\u00a0were more common in the treatment arm and included\u00a0included\u00a0pain, fever, chills, muscle ache, and malaise. No serious adverse events were reported. Cell-mediated immunity peaked on&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/07\/24\/safety-and-immunogenicity-of-the-chadox1-ncov-19-vaccine-against-sars-cov-2-a-preliminary-report-of-a-phase-1-2-single-blind-randomised-controlled-trial\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[31],"class_list":["post-8476","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=8476"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8476\/revisions"}],"predecessor-version":[{"id":8477,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8476\/revisions\/8477"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=8476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=8476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=8476"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=8476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}